author-photo

Chris Torrance

21

Papers

90

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

2016 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (56)
Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.

2014 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (16)
Abstract 3136: X‐MAN™ isogenic DualXenoTM models with KRAS mutation predicts the effect of anti-EGFR agents

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 4620: Wild-type IDH1: A molecular target in IDH1 mutant cancers

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2782: Utilization of in vivo human isogenic cancer models in the new era of targeted therapies.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 4289: 3-Dimensional growth reveals KRAS dependency.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Genome 2.0: First Form, Now Function

2013 Genetic Engineering & Biotechnology News
- Chris Torrance
Show All
- Source
- Cite
- Save
Citations (0)
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.

2012 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (14)
Abstract 2137: Using Rac1 isogenic cells to model tumor metastasis

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Enhancement of Hypoxia-Activated Prodrug TH-302 Activity by Chk1 Inhibition

2012
Show All
- Source
- Cite
- Save
Citations (0)